DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection

Details for Australian Patent Application No. 2006297130 (hide)

Owner Novartis AG

Inventors Burkey, Bryan; Allison, Malcolm; Hughes, Thomas Edward; Kemp, Daniel Matthew

Agent Davies Collison Cave

Pub. Number AU-B-2006297130

PCT Pub. Number WO2007/041368

Priority 60/722,629 30.09.05 US

Filing date 28 September 2006

Wipo publication date 12 April 2007

Acceptance publication date 24 December 2009

International Classifications

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

17 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041368 Priority application(s): WO2007/041368

24 December 2009 Application Accepted

  Published as AU-B-2006297130

22 April 2010 Standard Patent Sealed

26 April 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006297131-Improved advertising with audio content

2006297129-Oral composition containing a salivation inducing agent